Internal Medicine Department
The Hematology - Oncology Division
Research Information
Oncology Research Office -915.545.6510
Fax- 915.545.0966
Cancer Clinical Trials. We have numerous active clinical trials and many under review currently in our local IRB.
We have received a $1.5 million CPRIT grant to establish a “Cancer Clinical Research Core Facility”.http://www.cprit.state.tx.us/images/uploads/cfsa_slate_11022011.pdf
(Please keep checking the web site for updates on upcoming trials)
CURRENT CLINICAL TRIALS AT TTUHSC-EL PASO
Title: “AUY922 with Lapatinib and Letrozole for ER+, HER2+Advanced Breast cancer"
This study is reviewing whether administering infusions of the novel agent AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will benefit patients with advanced breast cancer known as ER+ HER2 +. All drugs are provided at no cost.
Principal Investigator: Zeina Nahleh MD
Status: Active
Age: Adult
Sponsor: Industry
Title: “A Phase III Randomized, Double-blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer”
This study is an international trial offering a combination of 2 oral agents and comparing its efficacy to single agent capecitabine ( All drugs are provided at no cost).
Local Principal Investigator: Zeina Nahleh MD
Status: Active
Age: Adult
Sponsor: Industry, global
Title: “Banking of Tissue and Establishing Continuous Cell Lines and Xenografts from Neoplasia, in collaboration with South Plains Oncology Consortium (SPONC) and the Texas Cancer Research Biobank (TCRB)”
This study is banking tumor tissue (any type of cancer) and matching it with normal cells enables studies to improve the understanding of cancer biology, and to develop improved diagnostic, prognostic, and therapeutic approaches.
Principal Investigator: Patrick Reynolds, MD, PhD(Lubbock)
Local Principal Investigator: Zeina Nahleh MD
Status: Active
Age: Adult
Sponsor: CPRIT
Title: S1007 “A Phase III, Randomized Clinical Trial Standard Adjunvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positives Nodes, Hormone Receptors-Positive and HER-2 Negative Breast Cancer Score (RS) of 25or less.”
The study objective is to determine the effect of chemotherapy in patients with node positive breast cancer who do not have high Recurrence Score (RS) by Oncotype DX®. Patients with 1-3 positive nodes, and hormone receptor (HR)-positive, HER2-negative breast with RS ≤ 25 treated with endocrine therapy we will test whether the difference in disease-free survival for patients treated with chemotherapy compared to no chemotherapy depends directly on the magnitude of RS.
Local Principal Investigator: Zeina Nahleh MD
Status: Active
Age: Adult
Sponsor: National Cancer Institute-SWOG
Title: “Effects of Chemotherapy on Markers of Metabolic Syndrome in Early Breast Cancer.”
The study objective is to study the effect of systemic chemotherapy on makers of metabolic syndrome in patients with early breast cancer.
Principal Investigator: Gaur, Sumit MD
Status: Active
Age: Adult
Sponsor: TTUHSC-Department of Internal Medicine
Title S0221: “Phase III Trial of Continuous Schedule AC + G Vs. 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer.”
This randomized phase III trial is studying the best schedule of adjuvant chemotherapy (dose dense or weekly).
Local Principal Investigator: Zeina Nahleh MD
Status:Recently Closed to Recruitment
Age: Adult
Sponsor: National Cancer Institute
Title:" Stage and Characteristic of Patients with Newly Diagnosed Breast Cancer at TTUHSC Breast Cancer Clinic El Paso"
This is an analysis of the large database of our breast cancer patients to understand the specific characteristics and features of the tumor and develop future research that address the specific needs of our patient population.
Principal Investigator: Zeina Nahleh MD
Status:Active
Age: Adult
Sponsor: CPRIT (through CCRC)
Title:" Launching a Breast Cancer Survivorship Program at TTUHSC-Paul Foster School of Medicine in El Paso"
The first phase of this project has been activated and we are conducting health surveys on our breast cancer survivors to better understand their needs, long term effects of treatment and gaps in their health resources. This will allow us to direct future research in this field based on the specific needs of our patient here in El Paso
Principal Investigator: Zeina Nahleh MD
Status:Active
Age: Adult
Sponsor: CPRIT (through CCRC)
For More Information, visit the National Cancer Institute's education page about cancer clinical trials at:
http://www.cancer.gov/clinicaltrials/